MARKET
consideration of $4 billion (Rs 240 billion) from Daiichi Sankyo Company in an all stock transaction. Upon closing, Daiichi Sankyo received 8.9 per cent stake in Sun Pharma. ◗ Japan-based Meiji Holdings acquired 100 per cent stake in Medreich for Rs 1,750 crores ◗ Strides Arcolab acquired 100 per cent stake in Shasun Pharma for Rs 1,300 crores ◗ Aurobindo Pharma acquired commercial operations of Actavis Group for total consideration of $ 40.76 million (Rs 240 crores). ◗ Aurobindo Pharma acquired US-based Natrol Inc for approximately $132.5 million (Rs 814 crores) ◗ Torrent Pharma acquired branded formulations business of Elder Pharma in India and Nepalfor a total consideration of $ 322 million (Rs 2,000 crores). Which are the big deals in the offing for the pharma and healthcare sector in 2015? Shetkar: They are: ◗ Parkway Hospital of Singapore has acquired 51 per cent stake in Hyderabad-based 750-bed Continental Hospital for Rs 250 crores ◗ There are deals under progress in Seven Hills Hospital (Mumbai), Global Hospitals (Hyderabad), MedPlus (Pharmacy Chain) ◗ Daiichi Sankyo sold its entire 8.9 per cent stake in Sun Pharma for $3 billion ◗ Torrent Pharma is planning to acquire the dermatology business of Mumbaiheadquartered Encore group in a deal size of Rs 350 crores ◗ Mylan Inc entered into a definitive agreement to acquire women's health business in Mumbai-based Famy Care for $ 800 million (Rs 4,956 crores). How will the tax proposals announced during Budget 2015 help both in-bound as well as out-bound M&As in theboth industries? Shetkar: Increase of insurance cover will boost health insurance and indirectly benefit delivery providers and 100 per cent FDI permission in the medical equipment sector
EXPRESS HEALTHCARE
17
June 2015
will facilitate M&A transactions. What are your predictions for the coming months? Bhageria: With steady demand being witnessed across therapy segments and price hikes taken by companies in line with Drug Price Control
Order (DPCO) guidelines, we expect growth momentum to sustain in the near-to-medium term. One important industry move that you would like to highlight? Shetkar: The national drug
pricing regulator, National Pharmaceutical Pricing Authority (NPPA) intensified its bid to control prices of medicines in order to make them affordable. In a move aimed to bring down prices of some of the key medicines, NPPA fixed the price of 108
non-scheduled formulation packs of 50 anti-diabetes and cardiac medicines. However, it had to withdraw internal guidelines for further such price control actions issued under Para 19 of the DPCO, 2013 later. raelene.kambli@expressindia.com